The Healthcare CEO’s Checklist: Proving EBITDA Quality Before You Hire an Advisor

Key Takeaways

1. High-quality EBITDA is essential for attracting the right buyers and maximizing deal value.
2. CEOs should normalize EBITDA and document add-backs transparently before engaging advisors.
3. Misstated or unclear EBITDA can derail deals and reduce buyer confidence.
4. Professional quality of earnings (QoE) reviews enhance credibility with buyers and healthcare M&A advisors.
5. Preparing a comprehensive financial checklist saves time, prevents surprises, and strengthens negotiation positions.

Why EBITDA Quality Matters for Healthcare CEOs

In today’s competitive healthcare M&A landscape, the stakes are higher than ever. Buyers scrutinize every line of your financial statements, and the credibility of your EBITDA often determines whether a deal moves forward. Many healthcare CEOs underestimate the impact of EBITDA quality on the transaction process, assuming that prospective buyers or healthcare business brokers will accept their numbers at face value. In reality, a poorly prepared EBITDA can signal financial mismanagement or hidden risks, causing hesitation—or worse, deal collapse.

EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is not just a number; it’s a story about the operational health of your practice. Buyers and healthcare M&A advisors rely heavily on this figure to assess cash flow potential, determine valuation multiples, and evaluate growth sustainability. When EBITDA is inflated or not properly normalized, it creates friction during due diligence, leading to lost trust and reduced offers.

The CEO’s Pre-Advisory Financial Checklist

Before engaging a healthcare M&A advisor, it’s crucial to conduct a comprehensive internal review. This checklist ensures your financials reflect the true performance of your business and positions you for a smoother, faster, and more lucrative transaction.

Step 1: Review and Normalize Your EBITDA

Normalization involves adjusting your EBITDA to reflect the true recurring earnings of your business. Common adjustments include removing one-time expenses, personal owner costs, or extraordinary revenue events. By presenting a clean, normalized EBITDA, you help buyers and advisors focus on sustainable operational performance rather than temporary fluctuations.

Step 2: Identify and Document Add-Backs Transparently

Add-backs are expenses that are removed from EBITDA because they do not reflect ongoing operational costs. Examples include one-off marketing campaigns, relocation costs, or non-essential equipment purchases. Transparency is key: each add-back should be documented with supporting invoices or explanations to avoid buyer skepticism.

Step 3: Highlight Non-Recurring Expenses Clearly

Many healthcare practices incur sporadic expenses that distort EBITDA. Whether it’s legal fees, staff training programs, or emergency equipment repair, clearly categorizing these costs ensures buyers understand they are non-recurring. This step helps healthcare business brokers present your practice in the best light during preliminary buyer discussions.

Common EBITDA Pitfalls That Reduce Deal Value

Even seasoned CEOs can fall into traps that reduce deal value. Understanding these pitfalls allows you to address them proactively.

Overstated Revenues or Hidden Liabilities

Inflated revenue reporting or unreported liabilities immediately raises red flags for buyers. This can lead to extended due diligence periods or even withdrawal of offers. Ensuring revenue is accurately reported and liabilities are fully disclosed builds confidence with your healthcare M&A advisors and prospective buyers alike.

Misclassified Expenses That Mislead Buyers

Misclassifying expenses, for example, treating owner perks or personal expenses as business costs, can artificially depress EBITDA. While it might seem beneficial in the short term, these inaccuracies often emerge during due diligence, undermining your credibility.

Ignoring Regulatory or Compliance Costs in EBITDA

Healthcare practices face strict regulatory requirements. Failing to account for recurring compliance costs, licensing fees, or mandatory reporting expenses can make EBITDA appear healthier than it truly is. A realistic EBITDA that includes these costs provides a more accurate picture for buyers and strengthens negotiation positions.

How Buyers and Advisors Evaluate EBITDA

Buyers and healthcare M&A advisors rarely take EBITDA at face value. They employ several methods to verify quality:

• Conducting a quality of earnings (QoE) review through independent accountants.
  
• Comparing your financials against industry benchmarks and multiples.
  
• Evaluating the consistency of revenue streams and recurring costs over multiple years.
  

Being proactive in these areas signals professionalism and transparency. A CEO who presents a well-prepared EBITDA reduces friction during due diligence and increases the likelihood of receiving competitive offers.

Validating EBITDA Before Engaging an Advisor

Ensuring your EBITDA is credible before introducing a healthcare M&A advisor can save significant time and protect deal value. Validation is about confirming that your reported earnings accurately reflect the true financial performance of your practice.

Commission a Professional Quality of Earnings (QoE) Review

One of the most effective ways to validate EBITDA is through a professional Quality of Earnings (QoE) review. This independent analysis identifies one-time or non-recurring items, verifies add-backs, and ensures your financials align with industry standards. A QoE review not only strengthens your credibility but also equips you with data-backed insights to negotiate confidently.

Internal Audit and Verification

Before external advisors get involved, conduct an internal audit. Compare current financials to historical records, cross-check invoices, and confirm revenue recognition practices. This process ensures no surprises arise during due diligence and demonstrates strong internal controls to buyers and healthcare business brokers.

Cross-Check Against Industry Benchmarks

Buyers often evaluate your EBITDA against peers in the healthcare sector. Consulting recent market reports or engaging a healthcare M&A advisor helps determine if your numbers are reasonable for your specialty and location. Being aware of market multiples enables you to proactively address any discrepancies.

Preparing Key Documents for Advisors and Buyers

Transparency and organization are critical when engaging healthcare M&A advisors or buyers. Having the right documentation ready can expedite the deal process and maximize valuation.

Financial Statements for the Last 3–5 Years

Provide complete income statements, balance sheets, and cash flow statements. Highlight trends and unusual fluctuations. Clear documentation reassures buyers and healthcare business brokers that the numbers are reliable.

Supporting Documentation for Add-Backs

Maintain invoices, contracts, or receipts that justify each add-back. Documenting why a cost is non-recurring or owner-specific builds trust and prevents disputes during negotiations.

Operational Metrics and Key Performance Indicators (KPIs)

Beyond financials, buyers want to see operational efficiency. Include patient volumes, revenue per service line, staff utilization, and other KPIs. Presenting operational data alongside EBITDA demonstrates a holistic understanding of your business performance.

Read more:  What a Healthcare CEO Should Demand From an M&A Advisor in 2026

Creating a Transparent Financial Narrative

Numbers alone do not tell the full story. CEOs who can articulate a clear financial narrative alongside their EBITDA gain a competitive edge.

Explain Revenue Fluctuations and One-Off Events

If certain periods experienced unusual spikes or drops in revenue, provide context. Whether it was a large one-time contract, seasonal trends, or temporary staffing changes, buyers appreciate transparency.

Show How Adjustments Reflect True Profitability

Walk advisors and potential buyers through how your add-backs, normalization, and expense adjustments accurately represent ongoing operations. A coherent narrative reinforces confidence in your numbers and can justify a higher valuation.

Demonstrate Strategic Investments and Growth Opportunities

Highlight investments in technology, staff training, or patient care that may temporarily reduce EBITDA but enhance long-term profitability. Buyers see the bigger picture and recognize potential value beyond immediate earnings.

Leveraging Advisors to Maximize Deal Value

Engaging experienced healthcare M&A advisors is not just about selling a practice, it’s about optimizing every aspect of the transaction. Advisors can:

• Provide insight on market trends and buyer preferences.
• Help structure deals to reflect EBITDA adjustments accurately.
• Facilitate connections with qualified buyers or private equity firms.

By ensuring your EBITDA is validated and well-documented before engaging an advisor, you position your practice for faster offers, smoother negotiations, and higher transaction value.

The Final CEO Checklist: Ensuring EBITDA-Ready for Sale or Partnership

A structured checklist helps CEOs ensure their EBITDA and financials are fully prepared before engaging healthcare M&A advisors. Following these steps minimizes surprises and maximizes deal value.

Step 1: Confirm Normalized EBITDA Accuracy

• Review all add-backs and non-recurring expenses.
  
• Ensure consistent methodology across multiple periods.
  
• Highlight adjustments in a clear, documented format for healthcare business brokers.
  

Step 2: Compile Supporting Documentation

• Income statements, balance sheets, cash flow reports for the last 3–5 years.
  
• Receipts, contracts, or invoices supporting add-backs.
  
• Operational metrics like patient volumes, service line revenues, and staff productivity.
  

Step 3: Conduct an Independent QoE Review

• Commission a professional Quality of Earnings report.
  
• Identify any discrepancies or areas that could raise buyer concerns.
  
• Use insights to refine your EBITDA narrative and strengthen negotiation power.
  

Step 4: Prepare for Advisor Engagement

• Ensure all financials are organized, transparent, and easily accessible.
  
• Discuss EBITDA assumptions, adjustments, and industry benchmarks with your healthcare M&A advisors.
  
• Establish clear communication on deal objectives and target buyers.
  

Step 5: Address Common Deal-Killers Proactively

• Misstated revenue or hidden liabilities.
  
• Misclassified expenses that distort EBITDA.
  
• Ignoring recurring regulatory and compliance costs.
  
• Lack of transparency in add-backs or one-off events.
  

Read more: What Sophisticated Buyers Expect From M&A Firms by 2026

Strengthening Buyer Confidence

By following this checklist, CEOs demonstrate financial maturity, operational control, and trustworthiness. Buyers and healthcare business brokers appreciate the transparency, and advisors can position your practice more favorably, often resulting in:

• Faster deal execution.
  
• Higher valuation multiples.
  
• Increased interest from qualified buyers.
  

Conclusion

Proving EBITDA quality is no longer optional for healthcare CEOs preparing to sell, merge, or partner. By normalizing earnings, documenting add-backs, conducting a QoE review, and collaborating with experienced healthcare M&A advisors and healthcare business brokers, CEOs ensure their practice is presented accurately, transparently, and confidently. This approach not only protects valuation but also streamlines the transaction process, allowing buyers to focus on the real growth potential of your practice.

FAQs

1. What is the main purpose of normalizing EBITDA?

Normalization removes one-time, non-recurring, or owner-specific expenses to reflect the true recurring earnings of a healthcare practice.

2. How do Quality of Earnings (QoE) reviews help CEOs?

QoE reviews validate EBITDA, uncover inconsistencies, and build buyer confidence, ultimately increasing transaction value.

3. When should a CEO engage a healthcare M&A advisor?

It’s best to engage an advisor after financials are validated and EBITDA is fully prepared, ensuring smoother negotiations and fewer surprises.

4. What documents should CEOs prepare for buyers?

Financial statements for 3–5 years, operational KPIs, add-back documentation, and compliance or regulatory cost records are essential.

5. Can misclassified expenses affect deal value?

Yes. Misclassified or unclear expenses can distort EBITDA, reduce buyer trust, and result in lower offers or delayed deals.